RT Journal Article
T1 Cost-minimization analysis of immunoglobulin treatment of primary immunodeficiency diseases in Spain
A1 Alsina, Laia
A1 Montoro, J. Bruno
A1 Moral, Pedro Moral
A1 Neth, Olaf
A1 Ortiz Pica, Marta
A1 Sánchez Ramón, Silvia María
A1 Presa, María
A1 Oyagüez, Itziar
A1 Casado, Miguel Ángel
A1 González Granado, Luis Ignacio
AB Primary immunodefciency diseases (PID), which are comprised of over 400 genetic disorders, occur when a component of the immune system is diminished or dysfunctional. Patients with PID who require immunoglobulin (IG) replacement therapy receive intravenous IG (IVIG) or subcutaneous IG (SCIG), each of which provides equivalent efcacy. We developed a costminimization model to evaluate costs of IVIG versus SCIG from the Spanish National Healthcare System perspective. The base case modeled the annual cost per patient of IVIG and SCIG for the mean doses (per current expert clinical practice) over 1 year in terms of direct (drug and administration) and indirect (lost productivity for adults and parents/guardians of pediatric patients) costs. It was assumed that all IVIG infusions were administered in a day hospital, and 95% of SCIG infusions were administered at home. Drug costs were calculated from ex-factory prices obtained from local databases minus the mandatory deduction. Costs were valued on 2018 euros. The annual modeled costs were €4,266 lower for patients with PID who received SCIG (total €14,466) compared with those who received IVIG (total €18,732). The two largest contributors were diferences in annual IG costs as a function of dosage (– €1,927) and hospital administration costs (– €2,688). However, SCIG incurred training costs for home administration (€695). Sensitivity analyses for two dose-rounding scenarios were consistent with the base case. Our model suggests that SCIG may be a cost-saving alternative to IVIG for patients with PID in Spain.
PB Springer Nature
SN 1618-7598
YR 2021
FD 2021-09-21
LK https://hdl.handle.net/20.500.14352/4611
UL https://hdl.handle.net/20.500.14352/4611
LA eng
NO CRUE-CSIC (Acuerdos Transformativos 2021)
DS Docta Complutense
RD 17 abr 2025